S

    Solid Biosciences LLC (SLDB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.77
    -0.36 (-3.55%)

    Market Cap: $1.03B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(15/35)
    Avg Surprise
    -3.41%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.41
    Range$-0.53 - $-0.34
    13 analysts
    EPS Revisions
    2
    0
    7d
    2
    9
    30d
    EPS Estimate Drift
    90d ago$-0.48-16.4%
    60d ago$-0.47-15.0%
    30d ago$-0.47-15.0%
    7d ago$-0.42-1.1%
    Current$-0.41
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.44
    Range$-1.07 - $-0.23
    13 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.44---
    Sep 26EST
    		-$-0.41---
    Jun 26
    Reported Aug 6
    		$-0.38$-0.43+11.63%Beat+9.5%
    Mar 26
    Reported May 12
    		$-0.52$-0.44-17.89%Miss+12.4%
    Dec 25
    Reported Mar 19
    		$-0.53$-0.52-1.92%Miss+47.0%
    Sep 25
    Reported Nov 3
    		$-0.48$-0.44-9.09%Miss+39.2%
    Jun 25
    Reported Aug 12
    		$-0.42$-0.49+14.29%Beat+31.1%
    Mar 25
    Reported May 15
    		$-0.59$-0.53-11.32%Miss+7.8%
    Dec 24
    Reported Mar 6
    		$-1.00$-0.78-27.84%Miss+0.0%
    Sep 24
    Reported Nov 6
    		$-0.79$-0.66-19.70%Miss+24.8%
    Jun 24
    Reported Aug 13
    		$-0.61$-0.66+7.58%Beat+51.6%
    Mar 24
    Reported May 15
    		$-0.64$-0.60-6.67%Miss+58.4%
    Dec 23
    Reported Mar 13
    		$-1.00$-0.99-1.01%Miss-47.1%
    Sep 23
    Reported Nov 8
    		$-1.05$-1.20+12.50%Beat+61.3%
    Jun 23
    Reported Aug 14
    		$-1.26$-1.41+10.64%Beat+59.7%
    Mar 23
    Reported May 11
    		$-1.54$-1.25-23.20%Miss+53.3%
    Dec 22
    Reported Mar 23
    		$-0.68N/A+58.79%Beat+71.7%
    Sep 22
    Reported Nov 10
    		$-2.71$-1.64-65.24%Miss-12.9%
    Jun 22
    Reported Aug 11
    		$-3.13$-2.92-7.19%Miss-22.7%
    Mar 22
    Reported Apr 27
    		$-3.30$-2.78-18.70%Miss-15.8%
    Dec 21
    Reported Mar 14
    		$-2.40$-2.91+17.53%Beat+48.4%
    Sep 21
    Reported Nov 3
    		$-2.40$-2.99+19.73%Beat+63.6%
    Jun 21
    Reported Aug 16
    		$-2.55$-2.83+9.89%Beat+56.4%
    Mar 21
    Reported May 14
    		$-2.85$-4.85+41.24%Beat+63.1%
    Dec 20
    Reported Mar 15
    		$-4.65$-5.09+8.64%Beat+52.3%
    Sep 20
    Reported Nov 5
    		$-6.60$-5.47-20.66%Miss+34.3%
    Jun 20
    Reported Aug 6
    		$-5.85$-7.45+21.48%Beat+48.7%
    Mar 20
    Reported May 7
    		$-7.72$-7.99+3.38%Beat+39.5%
    Dec 19
    Reported Mar 12
    		$-9.75$-9.14-6.67%Miss-1.6%
    Sep 19
    Reported Nov 12
    		$-10.05$-10.01-0.40%Miss-21.8%
    Jun 19
    Reported Aug 14
    		$-11.40$-11.59+1.64%Beat-46.2%
    Mar 19
    Reported May 13
    		$-12.75$-9.48-34.49%Miss-57.4%
    Dec 18
    Reported Mar 13
    		$-9.60$-9.10-5.49%Miss+28.1%
    Sep 18
    Reported Nov 13
    		$-8.25$-8.37+1.43%Beat-1486.5%
    Jun 18
    Reported Aug 10
    		$-7.80$-7.64-2.09%Miss-5471.4%
    Mar 18
    Reported May 10
    		$-8.10$-6.19-30.86%Miss-
    Dec 17
    Reported Jan 29
    		$-13.35$-8.95-49.16%Miss-
    Sep 17
    Reported Oct 23
    		$-0.52$0.00N/AMiss-
    Dec 16
    Reported Mar 30
    		$-0.14$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-5.12EV/EBITDA-3.69x
    Price/FCF-7.47xFCF Yield-13.38%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-65.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio13.82xQuick Ratio13.82x
    Trading Statistics
    Beta2.42Avg Volume882.01K
    52-Week High$11.4552-Week Low$3.79

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.50
    SMA 20$9.11
    SMA 50$9.17
    SMA 200$7.17
    EMA 10$9.54
    EMA 20$9.26
    EMA 50$8.86
    EMA 200$7.51

    MACD

    Line: 0.30Signal: 0.20Hist: 0.10

    ADX

    ADX: 16.7+DI: 31.7-DI: 20.8

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down8.0
    PSAR$8.91

    Bollinger Bands

    Upper Band$10.19
    Lower Band$8.03
    %B Position2368%(Upper)
    Band Width0.81

    RSI (14-Day)

    Neutral
    58.2

    Momentum Oscillators

    Stoch %K84.5
    Stoch %D86.4
    Williams %R-28.2
    ROC (10d)6.2%
    Momentum0.57
    CCI (20d)130.1
    MFI (14d)67.2

    Volatility Measures

    ATR (14d)$0.51(5.2%)
    StdDev (20d)0.54
    Hist Vol60.3%(High)

    Volume Flow

    VWAP$9.86
    OBV52.1M
    AD Line27.7M
    CMF (20d)0.185

    Volume Metrics

    Avg Vol (20d)874.9K
    Vol Ratio0.7x
    VWMA (20d)$9.12

    Pivot Points

    R3$10.68
    R2$10.48
    R1$10.30
    Pivot Point$10.10
    S1$9.92
    S2$9.72
    S3$9.54

    Advanced Oscillators

    TSI15.89
    Ultimate Osc56.2
    KST61.14

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$3.12M$0$0$0$4.74M$0
    Cost of Revenue$0$0$467,000$0$0$0$488,000$0$0$0$587,000$0
    Gross Profit$0$0$-467,000$0$0$0$-488,000$0$0$0$-587,000$0
    Operating Expenses$57.38M$57.31M$49.40M$48.06M$41.69M$40.05M$39.90M$35.18M$27.79M$26.86M$22.27M$23.11M
    R&D$44.27M$46.14M$38.13M$38.86M$32.41M$30.91M$30.77M$27.33M$19.46M$18.87M$15.45M$16.70M
    SG&A$13.12M$11.17M$11.27M$9.20M$9.28M$9.14M$9.13M$7.86M$8.33M$7.99M$6.81M$6.41M
    Operating Income$-57,384,000$-57,308,000$-49,403,000$-48,058,000$-41,693,000$-40,052,000$-39,896,000$-35,182,000$-27,788,000$-26,862,000$-22,265,000$-23,114,000
    Interest Income$3.22M$2.06M$2.05M$2.59M$2.97M$2.30M$1.93M$2.33M$2.56M$2.65M$1.76M$1.96M
    Interest Expense$0$0$5,000$-336,000$60,000$68,000$75,000$82,000$88,000$95,000$102,000$106,000
    Income Before Tax$-54,799,000$-56,737,000$-49,787,000$-45,776,000$-39,480,000$-39,282,000$-42,597,000$-32,725,000$-25,072,000$-24,303,000$-20,336,000$-20,980,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-54,799,000$-56,737,000$-49,787,000$-45,776,000$-39,480,000$-39,282,000$-42,597,000$-32,725,000$-25,072,000$-24,303,000$-20,336,000$-20,980,000
    EBITDA$-58,994,000$-59,025,000$-52,114,000$-48,649,000$-42,488,000$-41,419,000$-44,762,000$-35,774,000$-27,355,000$-27,072,000$-22,933,000$-23,232,000
    EBIT$-58,020,000$-58,801,000$-51,834,000$-48,698,000$-42,386,000$-41,514,000$-44,447,000$-34,971,000$-27,549,000$-26,859,000$-21,995,000$-22,836,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLDB

    News

    Truist Financial Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $20

    Truist Financial has initiated coverage on Solid Biosciences (SLDB.US) with a "Buy" rating. The firm has set a price target of $20 for the stock. This new rating and price target indicate a positive outlook from Truist Financial on Solid Biosciences.

    Moomoo•8/22/26•
    Bullish

    Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial

    Truist Financial initiated coverage on Solid Biosciences (NASDAQ:SLDB) with a "buy" rating and a $20.00 price target, suggesting a potential upside of over 111%. This positive sentiment aligns with a consensus "Moderate Buy" rating from analysts, with the company also beating its Q2 earnings estimates. Solid Biosciences, which develops gene therapies for Duchenne muscular dystrophy, has seen its stock trade up, with institutional investors owning a significant portion of its shares.

    MarketBeat•8/21/26•
    Bullish

    Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

    Solid Biosciences Inc. (NASDAQ:SLDB) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month price target of $17.11. The company's stock opened at $9.74, and institutional investors own a substantial 81.46% of its shares. Solid Biosciences recently reported a quarterly loss of $0.38 per share, outperforming the consensus estimate.

    MarketBeat•8/20/26•
    Bullish

    Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits

    Perceptive Advisors LLC and related entities, including Joseph Edelman, have reported a beneficial ownership of 12,046,579 shares in Solid Biosciences Inc. (NASDAQ: SLDB), representing an 11.2% stake. This includes common stock and pre-funded warrants, with the latter subject to a 9.99% beneficial ownership limitation preventing their current exercise. The filing details the breakdown of shares held by Perceptive Life Sciences Master Fund, Ltd. and Perceptive Xontogeny Venture Fund, LP, as well as stock options held by Adam Stone.

    Stock Titan•8/15/26•
    Neutral

    Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares

    Vestal Point Capital, along with its Chief Investment Officer Ryan Wilder, has reported a beneficial ownership of 4.8% in Solid Biosciences Inc. (SLDB). This stake includes 4,833,796 common shares, of which 2,673,796 are issuable upon the exercise of pre-funded common stock purchase warrants. The filing indicates shared voting and dispositive power over these shares, with the ownership percentage calculated based on 98,449,606 shares outstanding as of May 8, 2026.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About SLDB

    Does SLDB pay dividends?
    Solid Biosciences LLC (SLDB) does not currently pay a regular dividend.
    What is SLDB's market cap?
    Solid Biosciences LLC (SLDB) has a market capitalization of $1.03B with a current stock price of $9.77.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In